Overview of EU MDR for Orthopedic Manufacturers

 

EU Regulation 2017/745 (Medical Device Regulation, MDR) replaced the legacy Medical Device Directive (MDD, 93/42/EEC) on 26 May 2021, with a transition period ending 26 May 2024. As of 2026, all orthopedic implants placed on the EU market must comply with MDR requirements.

 

Key impacts for orthopedic manufacturers:

 

Significantly expanded scope and stricter classification rules.

Mandatory clinical evaluation with documented scientific literature review and clinical investigation for higher-risk devices.

Post-Market Clinical Follow-up (PMCF) as an ongoing obligation, not a one-time activity.

Unique Device Identification (UDI) system for all devices.

Registration in EUDAMED database.

Person Responsible for Regulatory Compliance (PRRC) per Article 15.

EU Authorised Representative (EC REP) required for non-EU manufacturers.

Notified Body capacity constraints have caused significant certification delays for the industry.

 

 

Device Classification for Orthopedic Implants

 

MDR uses a risk-based classification system (Annex VIII, 22 rules). For orthopedic implants:

 

Product MDR Rule Class Examples

Bone plates, screws, nails Rule 8 (implantable, long-term) IIb Locking plates, intramedullary nails, cortical/cancellous screws

Spinal fixation implants Rule 8 + Rule 8 special (spinal) IIb (some III) Pedicle screws, anterior cervical plates, PEEK cages

Total hip & knee prostheses Rule 8 + Rule 22 (active implantable contact) III Cementless hip stem, knee femoral component

External fixators Rule 8 / Rule 1 (non-active) IIa Ilizarov frame, monolateral fixator

Surgical instruments (drill bits, screwdrivers) Rule 6 (transient use) I (if non-measuring, non-sterile) Reusable instrument trays

Sterile-packed instruments Rule 6 + sterile condition Is (sterile Class I) Single-use sterile-packed instruments

CMF plates and screws Rule 8 IIb Mini plates, mesh plates, reconstruction plates

Bone void fillers, cements Rule 8 / Rule 21 IIb / III PMMA bone cement (III); calcium phosphate (IIb)

 

 

Conformity Assessment Routes

 

Depending on device class, the manufacturer chooses a conformity assessment route (Annex IX, X, or XI):

 

Class Routes Available Notified Body Role

I (non-sterile, non-measuring) Self-declaration (Annex VIII + DoC) None

Is (sterile Class I), Im (measuring) Annex IX or XI (production QA) Sterilization or measuring audit

IIa Annex IX (full QA) or X (type examination + production QA) Full QMS audit + technical documentation review (Annex IX) or type exam (Annex X)

IIb Annex IX (full QA) or X (type examination + production QA) Full QMS audit + technical documentation assessment per device family; or type examination + production QA

III (implantable) Annex IX or X (Annex X with notified body type exam + production QA) Full QMS + technical documentation assessment; CE certificate issued per device family; consultation with expert panel for novel devices

 

Most orthopedic manufacturers use Annex IX (full quality assurance) with their Notified Body. This route integrates ISO 13485 certification with CE marking and is the most efficient.

 

 

Technical File (Annex II)

 

The Technical File is the comprehensive evidence package supporting CE marking. For orthopedic implants, it must include:

 

Section Content

1. Device description and specification Product name, model, intended purpose, target patient population, materials, dimensions, sterilization method, accessories, variants

2. Information to be supplied with the device Label per Annex I Chapter III, IFU per Annex I Chapter III, packaging

3. Design and manufacturing information Design stages, manufacturing processes, suppliers of critical components, inspection procedures

4. General Safety and Performance Requirements (GSPR) Checklist mapping each GSPR (Annex I) to supporting evidence

5. Risk management Risk management plan, risk analysis (FMEA), risk management report per ISO 14971

6. Verification and validation Bench testing per ASTM/ISO standards, biocompatibility per ISO 10993, sterilization validation, packaging validation, MRI compatibility per ASTM F2503

7. Clinical evaluation Clinical Evaluation Report (CER) per MDR Annex XIV, including literature review, clinical investigation (if applicable), and post-market data

8. Post-market surveillance PMS plan, PMCF plan, PSUR (for Class IIa, IIb, III), vigilance procedures

9. Declaration of Conformity Signed DoC referencing MDR and applicable harmonized standards

 

 

Clinical Evaluation (Annex XIV)

 

Clinical evaluation is one of the most heavily audited areas under MDR. It must demonstrate that the device achieves its intended purpose and is safe and effective.

 

Three sources of clinical data are typically used for orthopedic implants:

 

Scientific literature — peer-reviewed clinical studies of the device or equivalent devices.

Clinical investigation — prospective study of the device under MDR Article 62-82; mandatory for many Class III implants unless sufficient equivalent-device data exists.

Post-market data — real-world data from PMS systems, registries, complaints, and PMCF studies.

 

For Class III implants, sufficient clinical evidence is required; demonstration of equivalence to an existing device is now more strictly assessed. Many manufacturers must conduct new clinical investigations.

 

 

Post-Market Clinical Follow-up (PMCF)

 

PMCF is a continuous process under MDR, not a one-time activity. For orthopedic implants:

 

PMCF plan — defines objectives, methods, timelines, milestones per device family.

PMCF studies — registry studies, surveys of users, retrospective chart reviews, or prospective observational studies.

PMCF evaluation report — annual summary of findings, conclusions on safety/performance, and impact on the risk-benefit determination.

PSUR (Periodic Safety Update Report) — required annually for Class IIa, IIb, III devices.

 

PMCF data must feed back into the Clinical Evaluation Report, Risk Management File, and Technical File as part of the lifecycle approach.

 

 

Unique Device Identification (UDI)

 

MDR Article 27 mandates UDI for all medical devices except custom-made devices. The system uses:

 

UDI carrier — DI (Device Identifier) + PI (Production Identifier) in human-readable and machine-readable (e.g., GS1, HIBCC, ICCBBA) formats.

UDI database (EUDAMED) — registration of DI, manufacturer, device characteristics, status.

Implementation timeline — Class III May 2021, Class IIa/IIb May 2023, Class I May 2025.

 

 

EU Authorised Representative (EC REP)

 

Non-EU manufacturers must designate an EC REP per MDR Article 11. The EC REP:

 

Acts as the manufacturer's liaison with EU competent authorities.

Maintains a copy of the Technical File and Declaration of Conformity.

Cooperates with competent authorities on vigilance and post-market surveillance.

Registers the manufacturer and devices in EUDAMED.

 

The EC REP must be established in an EU member state. Common EC REP service providers include Advena, Emergo by UL, RQM+, Johner Institute, and Obelis.

 

 

Person Responsible for Regulatory Compliance (PRRC)

 

Per MDR Article 15, every manufacturer must have at least one PRRC responsible for:

 

Ensuring conformity of devices with the QMS.

Preparation and maintenance of Technical Files and DoCs.

Post-market surveillance and vigilance obligations.

Statements in marketing materials and regulatory communications.

 

The PRRC must have relevant qualification (medical, pharmacy, engineering, or law degree plus 1 year regulatory experience, or 4 years regulatory experience).

 

 

Common Pitfalls and Audit Findings

 

Pitfall How to Avoid

Insufficient clinical evidence Build a robust CER with literature, PMS data, and PMCF studies; don't rely on legacy MDD dossiers

Inadequate PMCF plan Define specific objectives, measurable endpoints, timelines; not just "we will collect data"

GSPR checklist incomplete Address every GSPR; mark applicable with evidence citation; non-applicable must be justified

UDI not implemented correctly Verify issuing agency (GS1, HIBCC); assign Basic UDI-DI per device family; ensure carrier on label

PSUR missing or delayed Submit annually for Class IIa/IIb/III; align with NB certificate validity

EC REP not designated Appoint EC REP before placing device on EU market; update contract for ongoing role

EUDAMED registration incomplete Register as manufacturer; register devices; assign UDI; maintain data

Notified Body certificate scope mismatch Verify certificate covers your specific product codes (MDS codes under MDR)

 

 

Compliance Roadmap (New Manufacturer)

 

Gap analysis (1-2 months) — compare current QMS and technical documentation to MDR.

QMS upgrade to MDR (3-6 months) — update procedures for PMCF, PSUR, UDI, EUDAMED, PRRC.

Clinical evaluation upgrade (3-6 months) — perform literature search, assess clinical data sufficiency, conduct clinical investigation if needed.

Technical File preparation (6-12 months) — compile all sections per Annex II.

Notified Body engagement — apply early; capacity constraints mean 12-18 month wait times.

Stage 1 + Stage 2 audits — Notified Body audits for ISO 13485 and MDR Annex IX.

CE Certificate issued — valid for 5 years.

Post-market activities — maintain PMCF, PSUR, vigilance, EUDAMED.

 

Total timeline: typically 18-36 months for new manufacturers; 12-18 months for established manufacturers transitioning from MDD.

 

 

AOYE Medical — MDR Compliance Profile

 

AOYE Medical Technology (Changzhou) Co., Ltd. holds:

 

ISO 13485:2016 certification (TUV SUD)

CE marking under EU MDR 2017/745 (issued by accredited Notified Body)

FDA 510(k) clearance for select product families

Appointed EC REP for EU market access

EUDAMED registration active

 

For OEM partners and distributors, AOYE provides:

 

Declarations of Conformity

Technical Files / Design Dossiers (under NDA)

Material certificates and traceability records

Sterilization validation reports (per ISO 11137/11135/17665)

Biocompatibility summaries (per ISO 10993)

Country-specific registration support (510(k), ANVISA, TGA, PMDA, SFDA, etc.)

 

Request documentation at regulatory@aoyemedical.com.

 

 

Frequently Asked Questions

 

When did EU MDR 2017/745 become mandatory?

EU MDR 2017/745 became applicable on 26 May 2021. The transition period ended 26 May 2024 for most medical devices. As of 2026, all new orthopedic implants placed on the EU market must comply with MDR.

 

What class are orthopedic implants under MDR?

Most orthopedic implants are Class IIb (implantable, long-term). Total hip and knee prostheses are Class III. External fixators are typically Class IIa. Non-invasive instruments are Class I.

 

Do orthopedic implants require a Notified Body for CE marking under MDR?

Yes. All implantable orthopedic devices (Class IIa, IIb, III) require Notified Body involvement. Only some Class I non-sterile, non-measuring devices can use self-declaration.

 

What is the difference between MDD and MDR?

MDR is significantly more stringent: stricter clinical evaluation, mandatory PMCF, UDI, EUDAMED, PRRC, expanded scope, greater post-market surveillance, stricter classification.

 

What is the EU Authorised Representative (EC REP) requirement?

Non-EU manufacturers must designate an EC REP per MDR Article 11. The EC REP acts as liaison with EU competent authorities, maintains the Technical File, and handles vigilance reporting.

 

Does AOYE hold CE marking under MDR?

Yes. AOYE Medical holds CE marking under EU MDR 2017/745 for trauma, spine, joint, sports medicine, and CMF product families. We provide DoCs, Technical Files (under NDA), and country-specific registration support.